AYA.AX stock down 9.97% pre-market 17 Feb 2026: AI diagnostics outlook

AYA.AX stock opened pre-market at A$3.07, down 9.97% from the previous close after intraday trading showed a low of A$3.01 and volume of 372,628 shares. Investors are weighing Artrya Limited’s AI diagnostic traction for coronary disease against stretched valuation multiples and upcoming earnings on 24 Feb 2026. Today’s move reflects profit-taking after recent gains and signals rising short-term volatility as technical indicators show overbought readings while longer-term averages remain mixed. We examine fundamentals, technicals and Meyka AI forecasts to frame a risk-reward view for Australian AI healthcare exposure on the ASX.

Market snapshot: price, volume and recent moves

Artrya Limited (AYA.AX) trades on the ASX at A$3.07, down A$0.34 from the previous close of A$3.41, with a day range A$3.01–A$3.16 and market cap A$351.29M. Daily volume 372,628 is below the 50‑day average of 708,854, suggesting lighter trade on the drop. Year high is A$5.24 and year low A$0.56, reflecting episodic volatility and a 1‑year gain of 260.47%.

Business and AI positioning: Salix product and growth angle

Artrya’s Salix AI platform automates coronary CT angiography analysis to flag patients at risk of heart attack, giving AYA.AX an explicit AI product-market fit in medical imaging. Revenue traction remains small, but clinical validation and adoption milestones can translate into scalable software revenue if hospital procurement cycles accelerate. For more company context see StockAnalysis: Artrya profile and competitor comparisons on Investing.com.

Financials and valuation: losses, liquidity and ratios

AYA.AX shows trailing EPS -0.18 and negative PE -17.22, with book value per share A$0.21 and cash per share A$0.11, supporting a healthy current ratio 8.27. Price/Book sits at 15.00 and Price/Sales is extreme at 12,546.14, driven by low revenue per share A$0.00 and R&D intensity. These metrics mark AYA.AX as a growth-stage AI medtech stock with high valuation relative to current sales.

Technicals and trading signals for AYA.AX stock

Short-term indicators show RSI 70.89 and MFI 82.92, both signalling overbought conditions before today’s pullback, while ADX 40.86 implies a strong trend. The 50‑day average A$4.05 sits above the current price and the 200‑day average A$2.41 sits below, leaving mixed momentum across horizons. Traders should note ATR A$0.32 and Bollinger lower band A$3.23 for intraday support.

Meyka AI rates AYA.AX with a score out of 100 and forecast

Meyka AI rates AYA.AX with a score of 63.25 out of 100 — Grade B with a HOLD suggestion. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of A$3.56, a quarterly target of A$5.83 and a 12‑month forecast of A$7.90, implying a 12‑month upside of 157.44% from A$3.07; forecasts are model‑based projections and not guarantees.

Risks and catalysts for AI investors

Key risks include slow hospital adoption, regulatory steps, and the cash burn needed to scale, while catalysts are clinical trial wins, hospital rollouts, and recurring software revenue recognition. AYA.AX faces sector headwinds in healthcare where average PB is 4.49, making Artrya’s PB 15.00 notably higher and sensitive to operational execution and revenue proof points.

Final Thoughts

Key takeaways for AYA.AX stock in this pre‑market session: the share price sits at A$3.07 after a -9.97% move, reflecting profit taking against recent gains and overbought technical readings. Fundamentals show an early‑stage AI medtech with EPS -0.18, strong current liquidity (current ratio 8.27) but high valuation metrics such as Price/Book 15.00 and Price/Sales 12,546.14. Meyka AI’s forecast model projects A$7.90 at 12 months, implying ~157.44% upside versus the current price, while a nearer‑term monthly target is A$3.56 and a quarterly target A$5.83. Investors should balance the upside in AI diagnostics against execution risk, upcoming earnings on 24 Feb 2026, and sector comparables in Healthcare. We use Meyka AI as an AI‑powered market analysis platform to frame probabilistic scenarios; forecasts are model‑based projections and not guarantees. For traders, watch volume recovery above the 50‑day average 708,854 and clinical or contract news for directional confirmation.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.